Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 9.5% Higher on Analyst Upgrade

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s share price traded up 9.5% during mid-day trading on Thursday after Citizens Jmp raised their price target on the stock from $8.00 to $10.00. Citizens Jmp currently has a market outperform rating on the stock. Ironwood Pharmaceuticals traded as high as $3.74 and last traded at $3.68. 546,465 shares were traded during trading, a decline of 90% from the average session volume of 5,501,308 shares. The stock had previously closed at $3.36.

Other equities research analysts have also recently issued research reports about the stock. Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Wells Fargo & Company increased their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the company an “equal weight” rating in a report on Monday, January 5th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.93.

Ironwood Pharmaceuticals News Summary

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $450–$475 million and reiterated a strong outlook; LINZESS showed continued demand growth (11% EUTRx), which supports the higher top‑line guide. Ironwood Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrade from Citizens JMP: price target raised to $10 with a “market outperform” rating — a significant bullish signal that can attract buyers and supports the stock’s rally. Benzinga
• Positive Sentiment: The company reiterated 2025 results achievement and provided investor materials (slide deck) and the conference‑call transcript, giving investors more transparency into drivers of the guide and product performance. Slide Deck
• Neutral Sentiment: Full Q4 earnings call transcript and presentation are available for review; these provide detail on cost structure, guidance assumptions and timing that investors will parse for clarity. Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.01) vs. $0.02 expected and revenue of $47.7M vs. ~$86.1M consensus (revenue down ~47% YoY). The sizable miss and year‑over‑year revenue decline are the primary near‑term negative catalysts. Zacks: Q4 Earnings and Revenues Fall Shy
• Negative Sentiment: A Seeking Alpha piece downgraded the stock after reporting a pipeline setback and an extended timeline for Apraglutide, raising execution and timing risk for future growth catalysts. Seeking Alpha: Downgrading On Pipeline Setback

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC boosted its holdings in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the last quarter. Focus Partners Advisor Solutions LLC boosted its stake in shares of Ironwood Pharmaceuticals by 284.6% in the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after buying an additional 29,409 shares during the last quarter. LSV Asset Management acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $30,000. Captrust Financial Advisors purchased a new position in Ironwood Pharmaceuticals during the second quarter valued at approximately $32,000. Finally, Jump Financial LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $34,000.

Ironwood Pharmaceuticals Trading Up 8.9%

The company has a 50-day simple moving average of $4.28 and a 200 day simple moving average of $2.80. The firm has a market cap of $595.41 million, a PE ratio of 28.15 and a beta of 0.17.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. The firm had revenue of $47.71 million for the quarter, compared to analysts’ expectations of $86.10 million. On average, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.